Aptinyx Conducts Phase 2 Trials of Investigational Therapy for Neuropathic Pain and Fibromyalgia
News
The biopharmaceutical company Aptinyx recently announced updates regarding its two Phase 2 clinical trials evaluating the company’s lead therapy candidate, NYX-2925. This therapy aims to treat pain associated with fibromyalgia and neuropathic ... Read more